Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000921895-25-001483·Rein Therapeutics, Inc.
Schedule 13G ownership disclosure
REIN THERAPEUTICS INC
Common Stock, $0.001 par value · CUSIP: 00887A204
Event date: 2025-05-08
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Voss Value Master Fund, LP
Shares: 583,206.00 · Class: 2.5%
- Voss Value-Oriented Special Situations Fund, LP
Shares: 316,768.00 · Class: 1.4%
- Voss Advisors GP, LLC
Shares: 899,974.00 · Class: 3.9%
- Voss Capital, LP
Shares: 1,277,856.00 · Class: 5.6%
- Cocke Travis W.
Shares: 1,277,856.00 · Class: 5.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000921895-25-001483
- Form type
- SCHEDULE 13G
- Filer
- Rein Therapeutics, Inc.
- CIK
- CIK 1420565
- Filed
- May 14, 2025
- Reporting period
- May 08, 2025
- Description
- Schedule 13G beneficial ownership